Nitric oxide down-regulates topoisomerase i and induces camptothecin resistance in human breast MCF-7 tumor cells

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Sharma, Nilesh K ^a,b   Kumar, Ashutosh ^a   Kumari, Amrita ^a   Tokar, Erik J ^a   Waalkes, Michael P ^a   Bortner, Carl D ^a   Williams, Jason ^a   Ehrenshaft, Marilyn ^a   Mason, Ronald P ^a   Sinha, Birandra K ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b DR D Y PATIL BIOTECHNOLOGY AND BIOINFORMATICS INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; DNA; DNA TOPOISOMERASE; NITRIC OXIDE; PROTEIN BCL 2; PROTEIN P53; UBIQUITIN; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; TOP1 PROTEIN, HUMAN;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DNA CLEAVAGE; DOWN REGULATION; DRUG RESISTANCE; ENZYME ACTIVITY; HT 29 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MCF 7 CELL LINE; NITROSATION; PROTEIN DEGRADATION; PROTEIN STABILITY; UPREGULATION; WILD TYPE; BREAST NEOPLASMS; CELL SURVIVAL; DRUG EFFECTS; GENETICS; HT-29 CELL LINE; MCF-7 CELL LINE; METABOLISM; TUMOR CELL CULTURE;

BREAST NEOPLASMS; CAMPTOTHECIN; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE I; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; HT29 CELLS; HUMANS; MCF-7 CELLS; NITRIC OXIDE; TOPOISOMERASE I INHIBITORS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84951310580     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141897     Document Type: Article

References (53)

1. Davis KL, Martin E, Turko IV, Murad F. Novel effects of nitric oxide. Annu Rev Pharmacol Toxicol. 2001; 41:203-36. Epub 2001/03/27. doi: 10.1146/annurev.pharmtox.41.1.203 PMID: 11264456.
2. Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG. The role of nitric oxide in cancer. Cell Res. 2002; 12 (5-6):311-20. Epub 2003/01/17. doi: 10.1038/sj.cr.7290133 PMID: 12528889.
3. Ridnour LA, Thomas DD, Donzelli S, Espey MG, Roberts DD, Wink DA, et al. The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal. 2006; 8(7-8):1329-37. Epub 2006/08/17. doi: 10.1089/ars.2006.8.1329 PMID: 16910780.
4. Zhou J, Brune B. NO and transcriptional regulation: from signaling to death. Toxicology. 2005; 208 (2):223-33. Epub 2005/02/05. doi: 10.1016/j.tox.2004.11.021 PMID: 15691587.
5. Hall CN, Garthwaite J. What is the real physiological NO concentration in vivo? Nitric Oxide. 2009; 21 (2):92-103. Epub 2009/07/16. doi: 10.1016/j.niox.2009.07.002 PMID: 19602444; PubMed Central PMCID: PMC2779337.
6. Napoli C, Paolisso G, Casamassimi A, Al-Omran M, Barbieri M, Sommese L, et al. Effects of nitric oxide on cell proliferation: novel insights. J Am Coll Cardiol. 2013; 62(2):89-95. Epub 2013/05/15. doi: 10.1016/j.jacc.2013.03.070 PMID: 23665095.
7. Zhou J, Schmid T, Brune B. HIF-1alpha and p53 as targets of NO in affecting cell proliferation, death and adaptation. Curr Mol Med. 2004; 4(7):741-51. Epub 2004/12/08. PMID: 15579021.
8. Chanvorachote P, Nimmannit U, Stehlik C, Wang L, Jiang BH, Ongpipatanakul B, et al. Nitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitination. Cancer Res. 2006; 66(12):6353-60. Epub 2006/06/17. doi: 10.1158/0008-5472.can-05-4533 PMID: 16778213.
9. Li F, Sonveaux P, Rabbani ZN, Liu S, Yan B, Huang Q, et al. Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell. 2007; 26(1):63-74. Epub 2007/04/17. doi: 10.1016/j.molcel.2007.02.024 PMID: 17434127; PubMed Central PMCID: PMC2905600.
10. Chowdhury R, Godoy LC, Thiantanawat A, Trudel LJ, Deen WM, Wogan GN. Nitric oxide produced endogenously is responsible for hypoxia-induced HIF-1alpha stabilization in colon carcinoma cells. Chem Res Toxicol. 2012; 25(10):2194-202. Epub 2012/09/14. doi: 10.1021/tx300274a PMID: 22971010; PubMed Central PMCID: PMC3472092.
11. Godoy LC, Anderson CT, Chowdhury R, Trudel LJ, Wogan GN. Endogenously produced nitric oxide mitigates sensitivity of melanoma cells to cisplatin. Proc Natl Acad Sci U S A. 2012; 109(50):20373-8. Epub 2012/11/28. doi: 10.1073/pnas.1218938109 PMID: 23185001; PubMed Central PMCID: PMC3528548.
12. Gobert C, Bracco L, Rossi F, Olivier M, Tazi J, Lavelle F, et al. Modulation of DNA topoisomerase I activity by p53. Biochemistry. 1996; 35(18):5778-86. Epub 1996/05/07. doi: 10.1021/bi952327w PMID: 8639538.
13. Pommier Y, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, et al. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 1994; 12(5):530-42. Epub 1994/01/01. PMID: 7922710.
14. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem. 1995; 270(37):21429-32. Epub 1995/09/15. PMID: 7665550.
15. Stewart L, Redinbo MR, Qiu X, Hol WG, Champoux JJ. A model for the mechanism of human topoisomerase I. Science. 1998; 279(5356):1534-41. Epub 1998/03/21. PMID: 9488652.
16. Wang JC. DNA topoisomerases. Annu Rev Biochem. 1985; 54:665-97. Epub 1985/01/01. doi: 10. 1146/annurev.bi.54.070185.003313 PMID: 2992360.
17. Sinha BK. Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs. 1995; 49 (1):11-9. Epub 1995/01/01. PMID: 7705211.
18. Beidler DR, Cheng YC. Camptothecin induction of a time-and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol Pharmacol. 1995; 47(5):907-14. Epub 1995/05/01. PMID: 7538195.
19. Goldwasser F, Shimizu T, Jackman J, Hoki Y, O'Connor PM, Kohn KW, et al. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res. 1996; 56(19):4430-7. Epub 1996/10/01. PMID: 8813137.
20. Davis PL, Shaiu WL, Scott GL, Iglehart JD, Hsieh TS, Marks JR. Complex response of breast epithelial cell lines to topoisomerase inhibitors. Anticancer Res. 1998; 18(4C):2919-32. Epub 1998/08/26. PMID: 9713486.
21. Nieves-Neira W, Pommier Y. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways. Int J Cancer. 1999; 82(3):396-404. Epub 1999/07/10. PMID: 10399957.
22. Gupta M, Fan S, Zhan Q, Kohn KW, O'Connor PM, Pommier Y. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. Clin Cancer Res. 1997; 3(9):1653-60. Epub 1998/11/17. PMID: 9815856.
23. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene. 2003; 22(56):9030-40. Epub 2003/12/10. doi: 10.1038/sj.onc.1207116 PMID: 14663481.
24. Hasinoff BB, Wu X, Krokhin OV, Ens W, Standing KG, Nitiss JL, et al. Biochemical and proteomics approaches to characterize topoisomerase IIalpha cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIalpha. Mol Pharmacol. 2005; 67(3):937-47. Epub 2004/12/17. doi: 10.1124/mol.104.004416 PMID: 15602006.
25. Shih J-Y, Yuan A, Chen JJ-W, Yang P-C. Tumor-associated macrophage: its role in cancer invasion and metastasis. J Cancer Mol. 2006; 2(3):101-6.
26. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006; 66(2):605-12. Epub 2006/01/21. doi: 10.1158/0008-5472.can-05-4005 PMID: 16423985.
27. Lancaster JR Jr. Nitroxidative, nitrosative, and nitrative stress: kinetic predictions of reactive nitrogen species chemistry under biological conditions. Chem Res Toxicol. 2006; 19(9):1160-74. doi: 10.1021/tx060061w PMID: 16978020.
28. Wang YT, Piyankarage SC, Williams DL, Thatcher GR. Proteomic profiling of nitrosative stress: protein S-oxidation accompanies S-nitrosylation. ACS chemical biology. 2014; 9(3):821-30. doi: 10.1021/cb400547u PMID: 24397869; PubMed Central PMCID: PMC3985710.
29. Sinha BK, Bhattacharjee S, Chatterjee S, Jiang J, Motten AG, Kumar A, et al. Role of nitric oxide in the chemistry and anticancer activity of etoposide (VP-16,213). Chem Res Toxicol. 2013; 26(3):379-87. Epub 2013/02/14. doi: 10.1021/tx300480q PMID: 23402364; PubMed Central PMCID: PMC3697829.
30. Sinha BK, Kumar A, Bhattacharjee S, Espey MG, Mason RP. Effect of nitric oxide on the anticancer activity of the topoisomerase-active drugs etoposide and adriamycin in human melanoma cells. J Pharmacol Exp Ther. 2013; 347(3):607-14. Epub 2013/09/21. doi: 10.1124/jpet.113.207928 PMID: 24049059; PubMed Central PMCID: PMC3836306.
31. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science. 1989; 246(4933):1046-8. Epub 1989/11/24. PMID: 2555920.
32. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst. 1994; 86 (11):836-42. Epub 1994/06/01. PMID: 8182764.
33. Liu LF, Rowe TC, Yang L, Tewey KM, Chen GL. Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem. 1983; 258(24):15365-70. Epub 1983/12/25. PMID: 6317692.
34. Kolios G, Brown Z, Robson RL, Robertson DA, Westwick J. Inducible nitric oxide synthase activity and expression in a human colonic epithelial cell line, HT-29. Br J Pharmacol. 1995; 116(7):2866-72. Epub 1995/12/01. PMID: 8680718; PubMed Central PMCID: PMC1909228.
35. Tokar EJ, Person RJ, Sun Y, Perantoni AO, Waalkes MP. Chronic exposure of renal stem cells to inorganic arsenic induces a cancer phenotype. Chem Res Toxicol. 2013; 26(1):96-105. Epub 2012/11/10. doi: 10.1021/tx3004054 PMID: 23137061; PubMed Central PMCID: PMC3921970.
36. Saville B. A scheme for the colorimetric determination of microgram amounts of thiols. Analyst. 1958; 83(993):670-2.
37. Simon DI, Mullins ME, Jia L, Gaston B, Singel DJ, Stamler JS. Polynitrosylated proteins: characterization, bioactivity, and functional consequences. Proc Natl Acad Sci U S A. 1996; 93(10):4736-41. Epub 1996/05/14. PMID: 8643472; PubMed Central PMCID: PMC39348.
38. Gobert C, Skladanowski A, Larsen AK. The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53. Proc Natl Acad Sci U S A. 1999; 96(18):10355-60. Epub 1999/09/01. PMID: 10468612; PubMed Central PMCID: PMC17892.
39. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 1999; 285 (5434):1733-7. PMID: 10481009.
40. Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S, Kalyanaraman B. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)-and p53-dependent pathways. The Journal of biological chemistry. 2004; 279(24):25535-43. Epub 2004/04/01. doi: 10.1074/jbc.M400944200 PMID: 15054096.
41. Desai SD, Li TK, Rodriguez-Bauman A, Rubin EH, Liu LF. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res. 2001; 61(15):5926-32. Epub 2001/08/02. PMID: 11479235.
42. Desai SD, Liu LF, Vazquez-Abad D, D'Arpa P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem. 1997; 272(39):24159-64. Epub 1997/09/26. PMID: 9305865.
43. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 1996; 56(4):892-8. Epub 1996/02/15. PMID: 8631030.
44. Fan S, Smith ML, Rivet DJ 2nd, Duba D, Zhan Q, Kohn KW, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer research. 1995; 55(8):1649-54. Epub 1995/04/15. PMID: 7712469.
45. Chazotte-Aubert L, Hainaut P, Ohshima H. Nitric oxide nitrates tyrosine residues of tumor-suppressor p53 protein in MCF-7 cells. Biochem Biophys Res Commun. 2000; 267(2):609-13. Epub 2000/01/13. doi: 10.1006/bbrc.1999.2003 PMID: 10631110.
46. Chazotte-Aubert L, Pluquet O, Hainaut P, Ohshima H. Nitric oxide prevents gamma-radiation-induced cell cycle arrest by impairing p53 function in MCF-7 cells. Biochem Biophys Res Commun. 2001; 281 (3):766-71. Epub 2001/03/10. doi: 10.1006/bbrc.2001.4423 PMID: 11237724.
47. Calmels S, Hainaut P, Ohshima H. Nitric oxide induces conformational and functional modifications of wild-type p53 tumor suppressor protein. Cancer Res. 1997; 57(16):3365-9. Epub 1997/08/15. PMID: 9269997.
48. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000; 60 (1):184-90. Epub 2000/01/26. PMID: 10646872.
49. Jaiswal M, LaRusso NF, Nishioka N, Nakabeppu Y, Gores GJ. Human Ogg1, a protein involved in the repair of 8-oxoguanine, is inhibited by nitric oxide. Cancer Res. 2001; 61(17):6388-93. Epub 2001/08/28. PMID: 11522631.
50. Xu W, Liu L, Smith GC, Charles l G. Nitric oxide upregulates expression of DNA-PKcs to protect cells from DNA-damaging anti-tumour agents. Nat Cell Biol. 2000; 2(6):339-45. Epub 2000/06/15. doi: 10. 1038/35014028 PMID: 10854324.
51. Loibl S, Buck A, Strank C, von Minckwitz G, Roller M, Sinn HP, et al. The role of early expression of inducible nitric oxide synthase in human breast cancer. Eur J Cancer. 2005; 41(2):265-71. Epub 2005/01/22. doi: 10.1016/j.ejca.2004.07.010 PMID: 15661552.
52. Glynn SA, Boersma BJ, Dorsey TH, Yi M, Yfantis HG, Ridnour LA, et al. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest. 2010; 120(11):3843-54. Epub 2010/10/28. doi: 10.1172/jci42059 PMID: 20978357; PubMed Central PMCID: PMC2964971.
53. Heinecke JL, Ridnour LA, Cheng RY, Switzer CH, Lizardo MM, Khanna C, et al. Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression. Proc Natl Acad Sci U S A. 2014; 111(17):6323-8. Epub 2014/04/16. doi: 10.1073/pnas.1401799111 PMID: 24733928; PubMed Central PMCID: PMC4035989